Alligator Bioscience is advancing a differentiated pipeline of tumor-directed immunotherapies with a focus on the CD40 pathway and next-generation antibody formats. Our lead asset mitazalimab is currently in preparation for Phase 3 in metastatic pancreatic cancer, and is complemented by early-stage programs that support long-term growth in immuno-oncology.
Pipeline highlights:
- Tumor-directed immune activation via CD40
- Phase 3-ready lead candidate in pancreatic cancer
- Focused on high unmet medical need indications
- Platform built around mono- and bispecific antibody formats